Moderna

The Wall Street Journal analysis notes that market expectations for Moderna and Merck’s cancer vaccine mRNA-4157 may exceed what the data supports. While the vaccine showed promise in reducing recurrence risk in melanoma trials, sample sizes remain limited and long-term efficacy is unverified. Analysts caution that mRNA technology applications in oncology are still in early stages, and investors should be wary of short-term price volatility. Editor: GoodInfo Global News Team ...

Pharmaceutical giants Merck and Moderna have announced breakthrough results from their jointly developed mRNA cancer vaccine, which demonstrates significant efficacy in preventing melanoma recurrence. This milestone marks a new era in personalized cancer treatment, offering renewed hope to millions of cancer patients worldwide.

The US Food and Drug Administration has approved Moderna’s mRNA flu vaccine for commercial use, ending a years-long regulatory review and opening new applications for mRNA technology in infectious disease prevention.

[Flash] Moderna Stock Surges 14% on Hantavirus Vaccine Prospect Moderna (MRNA) shares jumped 14% as investors reacted positively to the company’s hantavirus vaccine development. The surge comes amid global attention on the hantavirus cruise ship outbreak, with investors optimistic about the vaccine’s commercial potential. Analysts advise monitoring clinical trial progress. Source: Google News